Barrett's esophagus is the transformation of normal esophageal squamous epithelium to specialized intestinal metaplasia (SIM). Among the Barrett's specialized cells, those that can develop protective mechanisms against apoptosis may have potential to become malignant. Studies have shown that overexpression of metallothionein (MT), low molecular protein that protects cells from apoptotic stimuli, appears to be associated with more advanced, highly malignant tumors. We thus investigated the relationship between MT expression and apoptosis in different stages of Barrett's carcinogenesis. Terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling and immunohistochemical dual-staining assay were performed in human biopsy samples of normal, SIM, dysplasia, and adenocarcinoma. Apoptotic index and MT expression were quantified by using an image system to analyze the converted digital data. A negative correlation between MT expression and apoptotic index was found. MT expression was significantly increased along with the histologic progression towards adenocarcinoma. This study thus suggests that MT may contribute to cytoprotection, thereby inhibiting apoptosis and leading to carcinogenesis of Barrett's esophageal cells.
BlotWJ, DevesaSS, KnellerRW, FraumeniJFJr.. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA265: 1287–1289, 1991.
2.
PeraM, CameronAJ, TrastekVF, CarpenterHA, ZinsmeisterAR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology104: 510–513, 1993.
3.
ReidBJ, BlountPL, RubinCE, LevineDS, HaggittRC, RabinovitchPS. Flow cytometric and histologic progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology102: 1212–1219, 1992.
4.
HameetemanW, TytgatGNJ, HouthoffHJ, Van Den TweelJG. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology96: 1249–1256, 1989.
5.
CameronAJ. Barrett's esophagus: Dose the incidence of adenocarcinoma matter?Am J Gastroenterol92: 193–194, 1997.
6.
JankowskiJA, WrightNA, MeltzerSJ, TriadafilopoulosG, GeboesK, CassonAG, KerrD, YoungLS. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol154: 965–973, 1999.
7.
LoweSW, LinAW. Apoptosis in cancer. Carcinogenesis21: 485–495, 2000.
8.
KatadaN, HinderRA, SmyrkTC, HirabayashiN, PerdikisG, LundRJ, WoodwardT, KlinglerPJ. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg132: 728–733, 1997.
9.
WhittlesCE, BiddlestoneLR, BurtonA, BarrH, JankowskiJA, WarnerPJ, ShepherdNA. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: A comparative study. J Pathol187: 535–540, 1999.
10.
WetscherGJ, SchwelbergerH, UngerA, OffnerFA, ProfanterC, GlaserK, KlinglerA, GadenstaetterM, KlingerP. Reflux-induced apoptosis of the esophageal mucosa is inhibited in Barrett's epithelium. Am J Surg176: 569–573, 1998.
11.
GoldblumJR, RiceTW. bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence. Mod Pathol8: 866–869, 1995.
12.
CoppolaD, SchreiberRH, MoraL, DaltonW, KarlRC. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncal6: 298–304, 1999.
13.
KangYJ. The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med222: 263–273, 1999.
14.
JasaniB, SchmidKW. Significance of metallothoinein overexpression in human tumors. Histopathology31: 211–214, 1999.
15.
OyamaT, TakeiH, HikinoT, LinoY, NakajimaT. Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferation activity, histology and prognosis. Oncology53: 112–117, 1996.
OhshioG, ImamuraT, OkadaN, WangZH, YamakiK, KyogokuT, SuwaH, YamabeH, ImamuraM. Immunohistochemical study of metallothionein in pancreatic carcinomas. J Cancer Res Clin122: 351–355, 1996.
18.
HishikawaY, KojiT, DharDK, KinugasaS, YamaguchiM, NagasueN. Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer81: 712–720, 1999.
19.
SamplinerSE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus: the Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol93: 1028–1032, 1998.
20.
ReidBJ, HaggittRC, RubinCE, RothG, SurawiczCM, Van BelleG, LewinK, WeinsteinWM, AntonioliDA, GoldmanH, MacDonaldW, OwenD. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol19: 166–178, 1988.
21.
HaggittRC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol25: 982–993, 1994.
22.
CaiL, SatohM, TohyamaC, CherianMG. Metallothionein in radiation exposure: its induction and protective role. Toxicology132: 85–93, 1999.
23.
DietrichJB. Apoptosis and anti-apoptosis genes in the Bcl-2 family. Arch Physiol Biochem105: 125–135, 1997.
24.
BennettMR. Mechanisms of p53-induced apoptosis. Biochem Pharmacol58: 1089–1095, 1999.
25.
NagataS. Fas ligand-induced apoptosis. Annu Rev Genet33: 29–55, 1999.
26.
CherianMG, HowellSB, ImuraN, KlaassenCD. Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol126: 1–5, 1994.
27.
HelalT, NassiriM, KhalifaA. Immunohistochemical markers of tumor prognosis in breast cancer in Egypt. Cancer Detect Prev21: 201–206, 1997.
28.
CohenJJ. Apoptosis: Mechanisms of life and death in the immune system. J Allergy Clin Immunol103: 548–554, 1999.
29.
EnemanJD, PottsRJ, OsierM, ShuklaGS, LeeCH, ChiuJF, HartBA. Suppressed oxidant-induced apoptosis in cadmium adapted alveolar epithelial cells and its potential involvement in cadmium carcinogenesis. Toxicology147: 215–228, 2000.
30.
WetscherGJ, HinderRA, KlinglerP, GadenstatterM, PerdikisG, HinderPR. Reflux esophagitis in humans is a free radical event. Dis Esophagus10: 29–32, 1997.
31.
Abdel-MageedA, AgrawalKC. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther4: 199–207, 1997.
32.
AroraV, IversenPL, EbadiM. Manipulation of metallothionein expression in the regenerating rat liver using antisense oligonucleotides. Biochem Biophys Res Commun246: 711–718, 1998.
33.
ApostolovaMD, CherianMG. Delay of M-phase onset by aphidicolin can retain the nuclear localization of zinc and metallothionein in 3T3-L1 fibroblasts. J Cell Physiol183: 247–253, 2000.
34.
CherianMG, ApostolovaMD. Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol46: 347–356, 2000.
CornellRP. Acute phase responses after acute liver injury by partial hepatectomy in rats as indicators of cytokine release. Hepatology11: 923–931, 1990.
37.
ChenML, FaillaML. Metallothionein metabolism in the liver and kidney of the streptozotocin-diabetic rat. Comp Biochem Physiol90: 439–445, 1988.
38.
MolotkovA, SatohM, TohyamaC. Induction of hepatic metallothioneins in tumor-bearing IL-6-null mice. Oncol Res12: 169–172, 2000.
39.
MinKS, MukaiS, OhtaM, OnosakaS, TanakaK. Glucocorticoid inhibition of inflammation-induced metallothionein synthesis in mouse liver. Toxicol Appl Pharmacol113: 293–298, 1992.
